TAMPA, Fla., June 18 /PRNewswire-FirstCall/ -- Nanobac Life Sciences, Inc. today announced that it exercised its right to take over the marketing and sales activity of its proprietary nanobiotic regimen from Pegasus Worldwide, Inc. Nanobacteria are associated with pathologic calcification in a variety of degenerative diseases including atherosclerosis (hardening of the arteries) and coronary heart disease. The company also announced that the International Journal of Pathophysiology accepted for publication the manuscript entitled "Calcification in Coronary Artery Disease can be reversed by EDTA - Tetracycline long-term chemotherapy" (DOI 10.1016/J.Pathophys.2004.06.001). The manuscript presents compelling data about the potential reversal of coronary artery calcification.
Supported by the International Journal of Pathophysiology manuscript, Nanobac will implement an ambitious and strategic sales and marketing effort for the nanobiotic through its wholly owned subsidiary, Nanobac Sciences. The Company anticipates recognizing revenue from this new sales initiative in the current quarter and also would expect strong sales growth over the next eighteen months.
Alex Edwards, Nanobac's President & Chief Executive Officer, stated, "The acceptance of this paper for publication in a peer reviewed journal is an important milestone; coupled with the clinical data we announced on April 27, it adds to the scientific foundation we are building to better understand the nature and role of nanobacteria in pathological calcification, as well as its detection and treatment." Mr. Edwards continued, "While we are retaining our focus on further defining the cause and effect relationship between Nanobacteria and vascular calcification, as well as other human diseases associated with pathological calcification, we are now positioned to pursue a combination diagnostic and therapeutic solution and anticipate immediate revenue from a new sales initiative for the nanobiotic."
About Nanobacteria
Nanobacterium sanguineum (nanobacteria) is the smallest self-replicating organism ever detected - at 50 to 500 billionths of a meter, 1/1000th the size of the smallest previously known bacteria. Nanobacteria have been implicated in a variety of human diseases associated with pathological calcification.
Nanobacteria were first discovered in 1988 by a Finnish researcher, and Nanobac OY co-Founder Olavi Kajander, M.D., Ph.D. Neva Ciftcioglu, Ph.D. joined his team in 1991 and their corroborated work with nanobacteria over the past 13 years has put them at the forefront of research into this medically important pathogen. Their research established that the blood-borne nanobacteria forms slow-growing calcified colonies in arteries and organs. Dr. Kajander participated in the current study.
Nanobac has identified two biomarkers of nanobacterial infection. These tests are being developed as the NB2 test, which is composed of the nanobacteria antigen test, and the nanobacteria IgG antibody test. The Nanobac IgG test is designed to measure the body's immune response to the nanobacterial infection. The Company is in the final stages of development of the nanobacteria antigen test.
About Coronary Artery Disease
Coronary artery disease (CAD) is the primary cause of death in the United States. More than 5 million people in the United States have coronary artery disease (CAD). When CAD is present, plaque buildup reduces blood flow through the arteries. If left untreated, CAD may result in a myocardial infarction, which is known as a heart attack.
About Nanobac
Nanobac Life Sciences, Inc. is dedicated to improving people's health through the detection and eradication of Nanobacterium sanguineum (nanobacteria). The Company's pioneering research is establishing the pathogenic role of nanobacteria in calcification, particularly in coronary artery heart disease and vascular disease. Nanobac has identified two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2(TM) ELISA assay to detect nanobacterial antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop the first FDA approved therapeutic to detect and treat nanobacterial infection. The Company currently markets, through its wholly owned subsidiary, Nanobac Sciences, a patented nanobiotic regimen that it developed.
Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobaclifesciences.com/.
Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.
For more information contact: Alex Edwards President / Chief Executive Officer Nanobac Life Sciences, Inc. 813-264-2241 Media: Cynthia Isaac, PhD The Ruth Group 646-536-7033 cisaac@theruthgroup.com
Nanobac Life Sciences, Inc.
Supported by the International Journal of Pathophysiology manuscript, Nanobac will implement an ambitious and strategic sales and marketing effort for the nanobiotic through its wholly owned subsidiary, Nanobac Sciences. The Company anticipates recognizing revenue from this new sales initiative in the current quarter and also would expect strong sales growth over the next eighteen months.
Alex Edwards, Nanobac's President & Chief Executive Officer, stated, "The acceptance of this paper for publication in a peer reviewed journal is an important milestone; coupled with the clinical data we announced on April 27, it adds to the scientific foundation we are building to better understand the nature and role of nanobacteria in pathological calcification, as well as its detection and treatment." Mr. Edwards continued, "While we are retaining our focus on further defining the cause and effect relationship between Nanobacteria and vascular calcification, as well as other human diseases associated with pathological calcification, we are now positioned to pursue a combination diagnostic and therapeutic solution and anticipate immediate revenue from a new sales initiative for the nanobiotic."
About Nanobacteria
Nanobacterium sanguineum (nanobacteria) is the smallest self-replicating organism ever detected - at 50 to 500 billionths of a meter, 1/1000th the size of the smallest previously known bacteria. Nanobacteria have been implicated in a variety of human diseases associated with pathological calcification.
Nanobacteria were first discovered in 1988 by a Finnish researcher, and Nanobac OY co-Founder Olavi Kajander, M.D., Ph.D. Neva Ciftcioglu, Ph.D. joined his team in 1991 and their corroborated work with nanobacteria over the past 13 years has put them at the forefront of research into this medically important pathogen. Their research established that the blood-borne nanobacteria forms slow-growing calcified colonies in arteries and organs. Dr. Kajander participated in the current study.
Nanobac has identified two biomarkers of nanobacterial infection. These tests are being developed as the NB2 test, which is composed of the nanobacteria antigen test, and the nanobacteria IgG antibody test. The Nanobac IgG test is designed to measure the body's immune response to the nanobacterial infection. The Company is in the final stages of development of the nanobacteria antigen test.
About Coronary Artery Disease
Coronary artery disease (CAD) is the primary cause of death in the United States. More than 5 million people in the United States have coronary artery disease (CAD). When CAD is present, plaque buildup reduces blood flow through the arteries. If left untreated, CAD may result in a myocardial infarction, which is known as a heart attack.
About Nanobac
Nanobac Life Sciences, Inc. is dedicated to improving people's health through the detection and eradication of Nanobacterium sanguineum (nanobacteria). The Company's pioneering research is establishing the pathogenic role of nanobacteria in calcification, particularly in coronary artery heart disease and vascular disease. Nanobac has identified two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2(TM) ELISA assay to detect nanobacterial antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop the first FDA approved therapeutic to detect and treat nanobacterial infection. The Company currently markets, through its wholly owned subsidiary, Nanobac Sciences, a patented nanobiotic regimen that it developed.
Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobaclifesciences.com/.
Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.
For more information contact: Alex Edwards President / Chief Executive Officer Nanobac Life Sciences, Inc. 813-264-2241 Media: Cynthia Isaac, PhD The Ruth Group 646-536-7033 cisaac@theruthgroup.com
Nanobac Life Sciences, Inc.
